Fundraising Fox

FibroBiologics

NASDAQ: FBLG

Houston, US · Founded 2021 · Delaware corporation

FibroBiologics develops fibroblast cell-based therapies for chronic and degenerative conditions, targeting areas such as multiple sclerosis and other autoimmune diseases, degenerative disc disease, wound healing, and age-related organ decline (thymus and spleen). The company is a clinical-stage biotech positioning fibroblasts as an alternative to stem cells for regeneration and immune modulation.

BiotechHealthtechLongevity

Founders & leadership

FibroBiologics was founded in 2021 by Pete O'Heeron.

POPete O'Heeron
Pete O'HeeronChairman, Founder and Chief Executive Officer
JDJason D. Davis
Jason D. DavisChief Financial Officer

Board

SC
Stacy CoenBoard director
ML
Matthew LinkBoard director
RH
Robert HoffmanBoard director
VN
Victoria NiklasBoard director
RC
Richard C. CilentoBoard director

Reported raises · per SEC filings

Form D private placements

$10.2M disclosed across 4 rounds · 2025–2026

▶$3MraisedJun 2026 · 1 investors · Pharmaceuticals
Rule 506(b)
FibroBiologics (NASDAQ: FBLG) discloses going-concern and Nasdaq bid-price risksstocktitan.net · Jul 2026FBLG: Advanced clinical pipeline, reduced R&D costs, raised $12M, and expanded patent assets — TradingView Newstradingview.com · Jul 2026
Officers, directors & promoters on the filing
  • Robert HoffmanDirector
  • Pete O'HeeronExecutive Officer, Director
  • Jason D. DavisExecutive Officer
  • Richard C. CilentoDirector
  • Victoria NiklasDirector
  • Matthew LinkDirector
Offering amount
$3M
Amount sold
$3M
Sales commissions
$315K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jun 2026
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7MraisedDec 2025 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert HoffmanDirector
  • Matthew LinkDirector
  • Stacy CoenDirector
  • Jason D. DavisExecutive Officer
  • Pete O'HeeronExecutive Officer, Director
  • Richard C. CilentoDirector
  • Victoria NiklasDirector
Offering amount
$1.7M
Amount sold
$1.7M
Sales commissions
$329.9K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Dec 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedDec 2025 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Pete O'HeeronExecutive Officer, Director
  • Jason D. DavisExecutive Officer
  • Richard C. CilentoDirector
  • Stacy CoenDirector
  • Victoria NiklasDirector
  • Matthew LinkDirector
  • Robert HoffmanDirector
Offering amount
$4M
Amount sold
$4M
First sale
Nov 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedDec 2025 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Stacy CoenDirector
  • Matthew LinkDirector
  • Robert HoffmanDirector
  • Victoria NiklasDirector
  • Pete O'HeeronExecutive Officer, Director
  • Jason D. DavisExecutive Officer
  • Richard C. CilentoDirector
Offering amount
$1.5M
Amount sold
$1.5M
Sales commissions
$292.2K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Nov 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Robinhood22 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies competing with FibroBiologics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2023$299.3K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2021$252K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

FBLG: Advanced clinical pipeline, reduced R&D costs, raised $12M, and expanded patent assets — TradingView Newstradingview.com · Jul 2026FibroBiologics (NASDAQ: FBLG) discloses going-concern and Nasdaq bid-price risksstocktitan.net · Jul 2026FibroBiologics Raises $3M With $9M Warrant Potentialallsci.com · Jul 2026FibroBiologics raises $3M in private placement offering By Investing.cominvesting.com · Jun 2026FibroBiologics raises $3M now, with $6M more possible if warrants are exercisedstocktitan.net · Jun 2026FibroBiologics Secures $5M Funding for Strategic Growth | Markets Insidermarkets.businessinsider.com · Dec 2024

Frequently asked questions

What does FibroBiologics do?
FibroBiologics develops fibroblast cell-based therapies for chronic and degenerative conditions, targeting areas such as multiple sclerosis and other autoimmune diseases, degenerative disc disease, wound healing, and age-related organ decline (thymus and spleen). The company is a clinical-stage biotech positioning fibroblasts as an alternative to stem cells for regeneration and immune modulation.
Who founded FibroBiologics?
FibroBiologics was founded by Pete O'Heeron in 2021.
How much funding has FibroBiologics raised?
FibroBiologics has disclosed $10.2M raised across 4 rounds.
Where is FibroBiologics headquartered?
FibroBiologics is headquartered in Houston, US.